Race-Specific prostate cancer drug trial seeks better control
NCT ID NCT03098836
Summary
This study tested a combination of two oral drugs, apalutamide and abiraterone acetate, plus prednisone in men with advanced prostate cancer that had stopped responding to standard hormone therapy. It specifically enrolled 50 African American and 50 Caucasian men to see how well the treatment worked in controlling the cancer and to monitor side effects like high blood pressure. The main goal was to see how long the cancer stayed under control without getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Chesapeake Urology Associates
Baltimore, Maryland, 21204, United States
-
Duke Cancer Center Cary
Cary, North Carolina, 27518, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Johnston Hematology and Oncology of Clayton
Clayton, North Carolina, 27520, United States
-
Johnston Memorial Hospital
Smithfield, North Carolina, 27577, United States
-
Maria Parham Hospital
Henderson, North Carolina, 27536, United States
-
Scotland Memorial Hospital
Laurinburg, North Carolina, 28352, United States
-
Southeastern Regional
Lumberton, North Carolina, 28358, United States
-
Spartanburg Regional
Spartanburg, South Carolina, 29303, United States
-
Tulane University
New Orleans, Louisiana, 70112, United States
-
UNC Lineberger Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
Virginia Oncology Associates
Hampton, Virginia, 29303, United States
-
Virginia Oncology Associates
Norfolk, Virginia, 23502, United States
Conditions
Explore the condition pages connected to this study.